Back to Search Start Over

High-Throughput Virtual Screening of Small Molecule Inhibitors for SARS-CoV-2 Protein Targets with Deep Fusion Models

Authors :
Stevenson, Garrett A.
Jones, Derek
Kim, Hyojin
Bennett, W. F. Drew
Bennion, Brian J.
Borucki, Monica
Bourguet, Feliza
Epstein, Aidan
Franco, Magdalena
Harmon, Brooke
He, Stewart
Katz, Max P.
Kirshner, Daniel
Lao, Victoria
Lau, Edmond Y.
Lo, Jacky
McLoughlin, Kevin
Mosesso, Richard
Murugesh, Deepa K.
Negrete, Oscar A.
Saada, Edwin A.
Segelke, Brent
Stefan, Maxwell
Torres, Marisa W.
Weilhammer, Dina
Wong, Sergio
Yang, Yue
Zemla, Adam
Zhang, Xiaohua
Zhu, Fangqiang
Lightstone, Felice C.
Allen, Jonathan E.
Publication Year :
2021

Abstract

Structure-based Deep Fusion models were recently shown to outperform several physics- and machine learning-based protein-ligand binding affinity prediction methods. As part of a multi-institutional COVID-19 pandemic response, over 500 million small molecules were computationally screened against four protein structures from the novel coronavirus (SARS-CoV-2), which causes COVID-19. Three enhancements to Deep Fusion were made in order to evaluate more than 5 billion docked poses on SARS-CoV-2 protein targets. First, the Deep Fusion concept was refined by formulating the architecture as one, coherently backpropagated model (Coherent Fusion) to improve binding-affinity prediction accuracy. Secondly, the model was trained using a distributed, genetic hyper-parameter optimization. Finally, a scalable, high-throughput screening capability was developed to maximize the number of ligands evaluated and expedite the path to experimental evaluation. In this work, we present both the methods developed for machine learning-based high-throughput screening and results from using our computational pipeline to find SARS-CoV-2 inhibitors.

Details

Database :
arXiv
Publication Type :
Report
Accession number :
edsarx.2104.04547
Document Type :
Working Paper